Format

Send to

Choose Destination
Cell Syst. 2019 Apr 24;8(4):345-351.e4. doi: 10.1016/j.cels.2019.03.011. Epub 2019 Apr 10.

N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer.

Author information

1
University of Toronto, Department of Medical Biophysics, Toronto, ON M5G 1L7, Canada.
2
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
3
Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY 10016, USA.
4
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada; Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY 10016, USA.
5
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada; University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON M5S 1A8, Canada.
6
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada; University of Toronto, Department of Obstetrics and Gynaecology, Toronto, ON M5G 1E2, Canada.
7
University of Toronto, Department of Medical Biophysics, Toronto, ON M5G 1L7, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
8
University of Toronto, Department of Medical Biophysics, Toronto, ON M5G 1L7, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada. Electronic address: thomas.kislinger@utoronto.ca.

Abstract

High-grade serous ovarian carcinoma (HGSC) is the most common and lethal subtype of gynecologic malignancy in women. The current standard of treatment combines cytoreductive surgery and chemotherapy. Despite the efficacy of initial treatment, most patients develop cancer recurrence, and 70% of patients die within 5 years of initial diagnosis. CA125 is the current FDA-approved biomarker used in the clinic to monitor response to treatment and recurrence, but its impact on patient survival is limited. New strategies for the discovery of HGSC biomarkers are urgently needed. Here, we describe a proteomics strategy to detect tumor-associated proteins in serum of HGSC patient-derived xenograft models. We demonstrate proof-of-concept applicability using two independent, longitudinal serum cohorts from HGSC patients.

KEYWORDS:

N-glycosylation; biomarker; ovarian cancer; patient-derived xenograft; serum proteomics; targeted proteomics

PMID:
30981729
DOI:
10.1016/j.cels.2019.03.011
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center